IraZackonMD

PubMed

• MPN-077 Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 3022 Patients With Polycythemia Vera (PV) Treated in US Community Practices.
  Roger M Lyons, Kathleen M Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum, Ira Zackon, Jingbo Yu> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 4 citations
  Hemorrhagic Cystitis Secondary to Adenovirus and BK Virus Infection in a Diffuse Large B-Cell Lymphoma Patient with Recent CAR T-Cell Therapy
  Abdul Moiz Khan, Zainub Ajmal, Fatima Tuz Zahra, Ananthakrishnan Ramani, Ira Zackon> ;Case Reports in Hematology. 2020 Nov 27
• 25 citations
  A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
  Jacob P. Laubach, Chia Jen Liu, Noopur Raje, Andrew Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jacquelyn Hedlund, Michael Gary Martin, Craig Reyno...> ;Clinical Cancer Research. 2019 Jan 15
• 1 citations
  Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer.
  Steven M. Grunberg, John W. Valentine, Ira Zackon, Paul Unger> ;Investigational New Drugs. 1995 Dec 1
• The effect of prolonged incubations and heat denaturation on melphalan-induced DNA cross-links as measured by the ethidium bromide fluorescence assay.
  Panasci, L., McQuillan, A., Cohen, J., Zackon, I.> ;Cancer Lett. 1990 Apr 20
• Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
  Anderson, L. M., Swaminathan, S., Zackon, I., Tajuddin, A. K., Thimmapaya, B., Weitzman, S. A.> ;Gene Ther. 1999 May
• Join now to see all

Journal Articles

• A Phase 1/2 Study of Evofosfamide, A Hypoxia-Activated Prodrug with or Without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma  
  Noopur S Raje, Ira Zackon, Clinical Cancer Research